InspireMD Q3 revenue beats analyst estimates

Overview

• US carotid stent developer's Q3 revenue rose yr/yr, beating analyst expectations

• Q3 net loss and income from operations were better than analyst estimates

• Company received FDA approval for CGuard Prime for TCAR, expanding U.S. market opportunity

Outlook

• InspireMD expects to begin U.S. sales of CGuard Prime for TCAR in Q4 2026

• Potential relaunch of CGuard Prime for CAS targeted for first half of 2027

Result Drivers

• US RECALL IMPACT - Co said voluntary recall of CGuard Prime for CAS delivery system led to lower US revenue and affected gross profit

• INTERNATIONAL SALES MIX - Co said international revenue grew, but sales shifted to countries with lower average prices, pressuring gross margin

• RESTRUCTURING COSTS - Co said operating expenses fell due to workforce reduction and related restructuring costs

Company press release:

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

• Wall Street's median 12-month price target for InspireMD Inc is $3.00, about 275% above its November 11 closing price of $0.80

Reuters Recommended Reads

• Nov 10 - Switzerland's Alcon Q3 sales slightly miss estimates despite surgical equipment launches, vision care growth

• Nov 10 - Surgical robotics firm Stereotaxis' Q3 revenue rises, but misses estimates

• Nov 10 - Carlsmed Q3 sales jump 65% on surgeon user growth, raises FY revenue guidance

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)